LAMPP Trial for Peripheral and Cutaneous T-Cell Lymphoma
Status:
Terminated
Trial end date:
2007-10-01
Target enrollment:
Participant gender:
Summary
Peripheral T cell lymphoma and advanced cutaneous T cell lymphomas are aggressive and
refractory diseases that are generally treated with chemotherapy. Despite current treatment
modalities, only a subset of patients will be cured by the treatment. In this study, four
chemotherapeutic agents (L-asparaginase, Methotrexate, Doxil, and Prednisone) will be
administered in a combination regimen for patients with relapsed or refractory Peripheral
and/or advanced cutaneous T cell lymphoma. Each one of these individual drugs have been shown
to have activity to lymphomas. The objective of the study is to determine if the combination
of these chemotherapy agents results in higher response and cure rates in this patient
population. This will be a single institutional study which will included 32 patients in the
Peripheral T cell lymphoma group and 32 patients in the Cutaneous T cell lymphoma group.
Phase:
N/A
Details
Lead Sponsor:
University of Medicine and Dentistry of New Jersey